Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 12-2024 | 09-2024 | 06-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 765,340 | 857,525 | 1,394,191 | 1,255,620 | 609,914 |
| Depreciation Amortization | 2,493,002 | 1,253,288 | 3,772,738 | 2,577,302 | 1,230,208 |
| Accounts receivable | 260,345 | 331,773 | -297,693 | -387,119 | -305,562 |
| Accounts payable and accrued liabilities | -76,446 | -191,682 | -115,157 | -248,429 | -239,712 |
| Other Working Capital | -316,560 | -828,835 | -953,099 | -1,811,888 | -1,215,865 |
| Other Operating Activity | 911,146 | 64,350 | 1,710,172 | 1,638,004 | 1,010,963 |
| Operating Cash Flow | $4,036,827 | $1,486,419 | $5,511,152 | $3,023,489 | $1,089,946 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -555,036 | -286,543 | -1,002,910 | -716,069 | -367,565 |
| Net Acquisitions | 191,141 | 202,108 | 63,294 | -157,142 | 18,822 |
| Purchase Of Investment | -5,794 | -1,484 | -629,402 | -185,818 | -83,072 |
| Sale Of Investment | 31,933 | 7,783 | 176,075 | 154,871 | 34,029 |
| Purchase Sale Intangibles | -271,218 | -187,370 | -890,333 | -613,398 | -514,285 |
| Other Investing Activity | -215,261 | -150,896 | -899,757 | -649,063 | -605,049 |
| Investing Cash Flow | $-553,017 | $-229,032 | $-2,292,701 | $-1,553,221 | $-1,002,835 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 3,577,208 | 1,266,530 | 6,761,436 | 6,595,882 | 3,248,883 |
| Debt Repayment | -3,176,729 | -864,542 | -5,174,921 | -1,902,927 | -320,698 |
| Common Stock Repurchased | -350,900 | -356,061 | -12,421 | -12,609 | -12,045 |
| Dividend Paid | -1,047,758 | -1,002,536 | -1,932,216 | -986,970 | -883,904 |
| Other Financing Activity | -544,612 | -526,201 | -2,609,456 | -2,310,924 | -7,399 |
| Financing Cash Flow | $-1,542,791 | $-1,482,810 | $-2,967,578 | $1,382,451 | $2,024,838 |
| Exchange Rate Effect | 74,317 | -16,802 | -11,121 | -164,579 | 110,208 |
| Beginning Cash Position | 2,618,768 | 2,657,280 | 3,021,480 | 3,067,260 | 2,929,920 |
| End Cash Position | 4,634,105 | 2,415,055 | 3,261,232 | 5,755,400 | 5,147,341 |
| Net Cash Flow | $2,015,336 | $-242,225 | $239,752 | $2,688,140 | $2,217,421 |
| Free Cash Flow | |||||
| Operating Cash Flow | 4,036,827 | 1,486,419 | 5,511,152 | 3,023,489 | 1,089,946 |
| Capital Expenditure | -598,454 | -330,600 | -1,003,213 | -716,324 | -367,622 |
| Free Cash Flow | 3,438,373 | 1,155,819 | 4,507,939 | 2,307,165 | 722,324 |